Legal & General Group
BCLI

Legal & General Group’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Legal & General Group’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-259
Closed -$15K – 3495
2021
Q1 		$15K Buy
259
+24
+10% +$1.81K ﹤0.01% 3239
2020
Q4 		$16K Hold
235
– – ﹤0.01% 3168
2020
Q3 		$60K Sell
235
-58
-20% -$11.9K ﹤0.01% 2629
2020
Q2 		$49K Buy
+293
New +$31.6K ﹤0.01% 2730

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Legal & General Group's BCLI Position: Q2 2021 in Review

Legal & General Group sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2021, closing a stake of 259 shares — an estimated $15K sold.

Legal & General Group first reported a position in BCLI in Q2 2020 and held it in 4 quarters. The position peaked at $60K in Q3 2020. 57 funds tracked by Wall St. Rank hold BCLI as of Q2 2021.

  • Legal & General Group reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2021 after selling out during the quarter.
  • Legal & General Group sold 259 BRAINSTORM CELL THERAPUTC shares in Q2 2021, an estimated $15K.
  • Legal & General Group first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2020 and held it in 4 quarters.
  • Legal & General Group's BRAINSTORM CELL THERAPUTC position peaked at $60K in Q3 2020.
  • 57 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2021.

Based on Legal & General Group's 13F filing for Q2 2021, filed 12 Aug 2021.